Mitochondrial Fission, Calcium, ROS in Right Ventricular Fibrosis
右心室纤维化中的线粒体裂变、钙、ROS
基本信息
- 批准号:10734675
- 负责人:
- 金额:$ 38.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-01 至 2027-06-30
- 项目状态:未结题
- 来源:
- 关键词:AntioxidantsApoptosisApoptoticAttenuatedBax proteinCalciumCardiacCardiac MyocytesCause of DeathCell Membrane PermeabilityCell NucleusChronicClinicalCollagenCyclic AMP-Dependent Protein KinasesDataDevelopmentDominant-Negative MutationDynaminEnzymesExtracellular MatrixFailureFibroblastsFibrosisFunctional disorderGoalsInjuryLeftLinkMediatingMitochondriaMitochondrial ProteinsModelingMolecularMyofibroblastNamesNuclearNuclear ProteinsOutcomeOuter Mitochondrial MembranePathologicPatientsPhenotypePhosphorylationPhysiologic intraventricular pressureProcessPrognosisProliferatingProtein InhibitionProteinsPulmonary HypertensionRattusReactive Oxygen SpeciesReportingResearchResistanceRight Ventricular FunctionRight Ventricular HypertrophyRoleSignal TransductionStressTestingVentricularconventional therapycoronary fibrosisdesignimprovedin vivointerstitialmitochondrial permeability transition poremortalitynovelnovel strategiesnovel therapeutic interventionnovel therapeuticspre-clinicalpressurepro-apoptotic proteinprotein kinase Dpulmonary arterial hypertensionresponseresponse to injuryright ventricular failuretherapeutic evaluationuptake
项目摘要
Project Summary:
Growing evidence suggests the link between right ventricular (RV) fibrosis, poor function of the pressure-overloaded
RV, and mortality in pulmonary arterial hypertension (PAH). PAH patients with decompensated RV failure (RVF) have
persistent RV fibrosis even when treated with the conventional therapies for PAH. RVF is the main cause of death in
PAH and maintaining RV function in PAH is associated with improved patient survival. However, there are currently no
available therapies that specifically target RV fibrosis. Therefore, identifying the molecular mechanisms underlying RV
fibrosis in PAH is urgently needed to develop novel therapeutic approaches targeting RVF in PAH.
We recently reported the significant roles of o
xidative stress-sensitive protein kinase
D (PKD) at outer
mitochondrial membrane (OMM) and its substrate dynamin-related protein 1 (DRP1), a mitochondrial fission protein, in
dysregulating CM functions. We also showed that DRP1-mediated mitochondrial fission limits the size of the matrix
cavity, thus causing elevated and sustained mitochondrial Ca2+ (mtCa2+) transient in response to cytosolic Ca2+ elevation.
Using a preclinical rat PAH model with RV hypertrophy, failure, and fibrosis that significant
, we found
PKD activation
and DRP1 phosphorylation occurs specifically
in cardiac fibroblasts (CFs) in the RV (RV-CFs), but not in CMs under
PAH, which subsequently causes an PKD-dependent increase in mitochondrial fission, mitochondrial reactive oxygen
species (mROS), and CF proliferation. Moreover, we found that PKD activation is associated with increased
phosphorylation of a pro-apoptotic protein Bax, which inhibits apoptotic pore formation in the OMM and potentially
contributes to the anti-apoptotic phenotype of RV-CFs in PAH. Lastly, we also found that mtCa2+ uptake via mtCa2+
uniporter (MCU) is required for mROS elevation and subsequent activation of proliferative signaling in CFs. Based on
these findings, we hypothesize that 1) PKD-dependent Bax phosphorylation allows RV-CFs to be resistant to apoptosis
under PAH; 2) PKD-dependent mitochondrial fission limits mtCa2+ and antioxidant capacity by decreasing the size of
the matrix cavity and causing increased mtCa2+ and mROS levels, thus acting as a molecular “switch” for proliferative
signaling for RV-CFs in PAH; and 3) CF-specific inhibition of PKD at the OMM in vivo can be leveraged as a novel
therapy to attenuate cardiac fibrosis in response to stress/injury such as PAH. In Aim 1, we will establish Bax as a novel
PKD substrate in the mitochondria and assess the impact of PKD-dependent Bax phosphorylation on OMM permeability.
To specifically inhibit PKD activity only at the OMM, we will use an OMM-targeted dominant-negative PKD1 (mt-PKD-
DN) that we have newly validated. In Aim 2, we will test whether PKD-dependent enhancement of mitochondrial fission
facilitates RV-CF proliferation via increased mtCa2+ and mROS levels. In Aim 3, we will test the therapeutic potential of
mitochondrial PKD inhibition by mt-PKD-DN in the quiescent CFs before they transform into myofibroblasts by CF-
specifically expressing mt-PKD-DN in a preclinical rat PAH model.
The proposed project is designed to determine the
role of mitochondrial fission, Ca2+, and mROS in RV-CF hyperproliferation and RV fibrosis in PAH, which will lead to
develop a novel strategy (i.e., PKD inhibition) for the management of RV fibrosis and failure in the setting of PAH.
项目概要:
越来越多的证据表明右心室(RV)纤维化与压力超载功能不良之间存在联系
RV 和肺动脉高压 (PAH) 死亡率。患有失代偿性右心室衰竭 (RVF) 的 PAH 患者
即使使用 PAH 的常规疗法进行治疗,仍会出现持续性 RV 纤维化。裂谷热是导致死亡的主要原因
PAH 和维持 PAH 中的 RV 功能与提高患者生存率相关。不过,目前还没有
专门针对 RV 纤维化的可用疗法。因此,确定 RV 的分子机制
迫切需要开发针对 PAH RVF 的新治疗方法。
我们最近报道了 o 的重要作用
氧化应激敏感蛋白激酶
D (PKD) 位于外侧
线粒体膜 (OMM) 及其底物动力相关蛋白 1 (DRP1)(一种线粒体裂变蛋白)
CM 功能失调。我们还表明 DRP1 介导的线粒体裂变限制了基质的大小
腔,从而导致线粒体 Ca2+ (mtCa2+) 短暂升高并持续,以响应胞质 Ca2+ 升高。
使用具有 RV 肥大、衰竭和纤维化的临床前大鼠 PAH 模型,显着
,我们发现
公钥簿激活
DRP1 磷酸化特异发生
存在于右心室 (RV-CF) 中的心脏成纤维细胞 (CF) 中,但不存在于 CM 中
PAH,随后导致线粒体裂变、线粒体活性氧的 PKD 依赖性增加
物种(mROS)和CF增殖。此外,我们发现 PKD 激活与增加
促凋亡蛋白 Bax 的磷酸化,可抑制 OMM 中凋亡孔的形成,并可能
有助于 PAH 中 RV-CF 的抗凋亡表型。最后,我们还发现 mtCa2+ 通过 mtCa2+ 摄取
mROS 升高和随后 CF 中增殖信号的激活需要单向转运蛋白 (MCU)。基于
根据这些发现,我们假设 1) PKD 依赖性 Bax 磷酸化使 RV-CF 能够抵抗细胞凋亡
根据多环芳烃; 2) PKD 依赖性线粒体裂变通过减小线粒体的大小来限制 mtCa2+ 和抗氧化能力
基质空腔并导致 mtCa2+ 和 mROS 水平增加,从而充当增殖的分子“开关”
PAH 中 RV-CF 的信号传导; 3) 体内 OMM 处的 CF 特异性抑制 PKD 可作为一种新的方法
减轻因压力/损伤(如肺动脉高压)而导致的心脏纤维化的治疗。在目标 1 中,我们将把 Bax 打造为一部小说
线粒体中的 PKD 底物并评估 PKD 依赖性 Bax 磷酸化对 OMM 通透性的影响。
为了仅在 OMM 处特异性抑制 PKD 活性,我们将使用 OMM 靶向显性失活 PKD1 (mt-PKD-
DN)是我们新近验证的。在目标 2 中,我们将测试线粒体裂变是否依赖于 PKD 增强
通过增加 mtCa2+ 和 mROS 水平促进 RV-CF 增殖。在目标 3 中,我们将测试以下药物的治疗潜力:
在静息 CF 转化为肌成纤维细胞之前,mt-PKD-DN 抑制线粒体 PKD
在临床前大鼠 PAH 模型中特异性表达 mt-PKD-DN。
拟议项目旨在确定
线粒体裂变、Ca2+和 mROS 在 PAH 中 RV-CF 过度增殖和 RV 纤维化中的作用,这将导致
开发一种新策略(即 PKD 抑制)来管理 PAH 情况下的 RV 纤维化和衰竭。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Bong Sook Jhun其他文献
Bong Sook Jhun的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似国自然基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
- 批准号:LBY21H010001
- 批准年份:2020
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
- 批准号:81703335
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
- 批准号:81670594
- 批准年份:2016
- 资助金额:58.0 万元
- 项目类别:面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
- 批准号:81470791
- 批准年份:2014
- 资助金额:73.0 万元
- 项目类别:面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
- 批准号:81301123
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
- 批准号:81101529
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
- 批准号:39500043
- 批准年份:1995
- 资助金额:9.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Spatial Restriction of Apoptotic Machinery during Neuronal Apoptosis and Pruning
神经元凋亡和修剪过程中凋亡机制的空间限制
- 批准号:
10596657 - 财政年份:2021
- 资助金额:
$ 38.75万 - 项目类别:
Spatial Restriction of Apoptotic Machinery during Neuronal Apoptosis and Pruning
神经元凋亡和修剪过程中凋亡机制的空间限制
- 批准号:
10417219 - 财政年份:2021
- 资助金额:
$ 38.75万 - 项目类别:
Examining the contribution of apoptosis repressor with caspase recruitment domain (ARC) to the anti-apoptotic effect of endurance training in skeletal muscle
检查具有半胱天冬酶募集结构域 (ARC) 的凋亡抑制因子对骨骼肌耐力训练的抗凋亡作用的贡献
- 批准号:
441952-2013 - 财政年份:2015
- 资助金额:
$ 38.75万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Doctoral
Examining the contribution of apoptosis repressor with caspase recruitment domain (ARC) to the anti-apoptotic effect of endurance training in skeletal muscle
检查具有半胱天冬酶募集结构域 (ARC) 的凋亡抑制因子对骨骼肌耐力训练的抗凋亡作用的贡献
- 批准号:
441952-2013 - 财政年份:2014
- 资助金额:
$ 38.75万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Doctoral
Understanding the activation of pro-apoptotic Bcl-2 family proteins for the development of modulators of apoptosis
了解促凋亡 Bcl-2 家族蛋白的激活以开发凋亡调节剂
- 批准号:
nhmrc : 1059331 - 财政年份:2014
- 资助金额:
$ 38.75万 - 项目类别:
Project Grants
Examining the contribution of apoptosis repressor with caspase recruitment domain (ARC) to the anti-apoptotic effect of endurance training in skeletal muscle
检查具有半胱天冬酶募集结构域 (ARC) 的凋亡抑制因子对骨骼肌耐力训练的抗凋亡作用的贡献
- 批准号:
441952-2013 - 财政年份:2013
- 资助金额:
$ 38.75万 - 项目类别:
Postgraduate Scholarships - Doctoral
Apoptotic Osteocytes Promote Chondrocyte Apoptosis via Soluble Factors
凋亡骨细胞通过可溶性因子促进软骨细胞凋亡
- 批准号:
251802 - 财政年份:2012
- 资助金额:
$ 38.75万 - 项目类别:
Studentship Programs
Defining the mechanism(s) by which the cellular inhibitor of apoptosis protein 2 (cIAP2) contributes to early stage atherosclerosis development by directly promoting the participation of key apoptotic pathways within lesion-associated macrophages
确定凋亡蛋白细胞抑制剂 2 (cIAP2) 通过直接促进病变相关巨噬细胞内关键凋亡途径的参与来促进早期动脉粥样硬化发展的机制
- 批准号:
191299 - 财政年份:2009
- 资助金额:
$ 38.75万 - 项目类别:
Operating Grants
ATP release during apoptosis and its relevance to apoptotic cell clearance
凋亡过程中 ATP 释放及其与凋亡细胞清除的相关性
- 批准号:
8075522 - 财政年份:2009
- 资助金额:
$ 38.75万 - 项目类别:
ATP release during apoptosis and its relevance to apoptotic cell clearance
凋亡过程中 ATP 释放及其与凋亡细胞清除的相关性
- 批准号:
7676912 - 财政年份:2009
- 资助金额:
$ 38.75万 - 项目类别: